FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
Human Drugs

Supply Chain Waiver Guidance

FDA issues a draft guidance on how drug supply chain trading partners can request a waiver, exception, or exemption from some specified requirements.

Biologics

Janssen sBLA for Multiple Myeloma Combo Therapy OKd

FDA approves a Janssen supplemental BLA to use Darzalex (daratumumab) in combination with bortezomib, melphalan and prednisone for treating patients w...

Medical Devices

Letter to MDs Updates Advice on Neurovascular Stents

A new FDA letter to healthcare professionals provides recommendations about patient selection and the use of neurovascular stents used for stent-assis...

Human Drugs

Massachusetts Court Clouds Innovator Lability: Attorney

Attorney Victor Schwartz says Massachusetts highest court allowed a reckless liability claim against Merck even though the plaintiff was injured by a ...

Human Drugs

FDA to Decide on Calcitriol Manufacturer by 8/19

FDA says it should respond by 8/19 to a Rockwell Medical submission seeking a contract manufacturer for its approved generic drug Calcitriol.

Medical Devices

Assess Full Cost of Software Pre-certification: Attorney

Attorney Bradley Thompson urges the medical device industry to weigh the downstream consequences of unbridled enthusiasm for FDAs proposed software pr...

Human Drugs

Relypsa sNDA Approved for Veltassa Label Update

FDA approves a Relypsa supplemental NDA for Veltassa (patiromer) for oral suspension in treating hyperkalemia.

FDA General

Latest FDA Warning Letters

FDA releases its latest batch of Warning Letters that includes Biotek Inc. and Dexcowin Co.

Human Drugs

AuroMedics Recalls Ampicillin and Sulbactam Lots

FDA says AuroMedics recalled two lots of ampicillin and sulbactam for injection due to complaints that it contained red particulate matter.

Human Drugs

FDA Chief Counsel on Upcoming First Amendment Work

In her annual address to the Food and Drug Law Institute, FDA chief counsel Rebecca Wood hints that the agency is working on a guidance on manufacture...